CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Clay Siegall

Former CEO, Seagen

Search every verified Clay Siegall interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Clay Siegall, co-founder and former CEO of Seagen (formerly Seattle Genetics), has described the company's focus on developing antibody-based cancer therapies. In a 2022 talk, he stated that the company's concept is "to make a difference in the life of cancer patients" using antibody drug conjugates. He noted that the company's first product, Adcetris, was approved by the FDA in 2011 and was available in 47 countries as of 2022. Siegall also discussed the company's patient assistance program, CGEN Secure, which he said was created to help with copay costs for patients in the United States and Canada. In a 2020 interview, Siegall discussed the early reception of Padcev, an antibody-drug conjugate for bladder cancer that received FDA approval in December 2019. He stated that the drug was "very active" and that doctors were "embracing it." Siegall reported a 73% objective response rate in a trial combining Padcev with tucatinib for first-line patients, calling the data "spectacular" but noting that larger trials were needed. He also mentioned that the company had submitted tucatinib data to the European Medicines Agency and was nearing approval in several other territories through Project Orbis.

Recent appearances

  • Founder Stories: Clay Siegall, Co-Founder and CEO of Seattle Genetics

    October 04, 2022 · 📺 Axial

    Clay Siegall co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his leadership, Seattle Genetics has built a diverse pipeline of antibody-based cancer therapies, including ADCETRIS (brentuximab vedotin) that was granted accelerated approval by the U.S. Food andDrug Administration (FDA) in 2011. Dr. Siegall has also guided Seattle Genetics/ capital-raising activities, securing more than $675 million through public and private financings, including the company’s initial public offering in 2001. Prior to co-fou…

    Watch on YouTube ↗

  • Seattle Genetics CEO on Q1 earnings, Padcev bladder cancer drug

    May 01, 2020 · 📺 CNBCTelevision

    Seattle Genetics CEO Clay Siegall discussed early reception of Padcev, an antibody-drug conjugate for bladder cancer that received FDA approval in December. For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/2JdMwO7 » Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision » Subscribe to CNBC: https://cnb.cx/SubscribeCNBC » Subscribe to CNBC Classic: https://cnb.cx/SubscribeCNBCclassic Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. Connect w…

    Watch on YouTube ↗

  • Seattle Genetics CEO: Addressing Unmet Needs | Mad Money | CNBC

    October 18, 2017 · 📺 CNBC

    Seattle Genetics' has put cancer squarely in its sights. Will the pipeline powered by its breakthrough science propel the stock higher? Jim Cramer spoke to CEO Clay Siegall to find out. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Seattle Genetics here: http://cnb.cx/2g15k4K "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pi…

    Watch on YouTube ↗

  • Seattle Genetics' Siegall `Excited' by Cancer Drug Data: Video

    March 23, 2012 · 📺 Bloomberg Originals

    Oct. 11 (Bloomberg) -- Clay Siegall, chief executive officer of Seattle Genetics Inc., discusses the results from a clinical trial of its SGN-35 drug for treating anaplastic large cell lymphoma. The drug, also known as brentuximab vedotin, uses an antibody to home in on cancer cells. Siegall, speaking with Betty Liu and Adam Johnson on Bloomberg Television's "In the Loop," also discusses the prospects that his company may become a takeover target. (Source: Bloomberg)

    Watch on YouTube ↗

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →